Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RRG EXM
- Development stage
- Preclinical
- Lead developer
- Regenesys
- Administration
- Topical, Implant
01
Overview
RRG EXM is an extracellular matrix (ECM) allograft developed by Regenesys. It is derived from human placental tissue and processed as a Human Cell, Tissue, and Cellular and Tissue-Based Product (HCT/P). The product provides an acellular scaffold that retains the structural and biochemical components of the native ECM, including collagen, proteoglycans, and growth factors. It is designed to support tissue regeneration and repair by providing a biological framework for host cell migration, proliferation, and differentiation in regenerative medicine applications.
- Brand names
- RRG EXM
- Other names
- Extracellular Matrix AllograftHuman placental tissue allograftHCT/P
Beyond the preview
Go deeper on RRG EXM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RRG EXM.